{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-08-27",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 2
    }
  },
  "results": [
    {
      "discontinued_date": "12/22/2025",
      "update_type": "New",
      "initial_posting_date": "12/22/2025",
      "package_ndc": "0002-8011-27",
      "generic_name": "Mirikizumab-mrkz Injection",
      "contact_info": "800-545-5979",
      "related_info": "A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.",
      "openfda": {
        "application_number": [
          "BLA761279"
        ],
        "brand_name": [
          "OMVOH"
        ],
        "generic_name": [
          "MIRIKIZUMAB-MRKZ"
        ],
        "manufacturer_name": [
          "Eli Lilly and Company"
        ],
        "product_ndc": [
          "0002-8011",
          "0002-7575",
          "0002-8870",
          "0002-7717",
          "0002-7722",
          "0002-3116",
          "0002-1442"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "SUBCUTANEOUS"
        ],
        "substance_name": [
          "MIRIKIZUMAB"
        ],
        "rxcui": [
          "2668391",
          "2668398",
          "2668405",
          "2668410",
          "2680728",
          "2680732",
          "2703047",
          "2703048",
          "2703049",
          "2703050",
          "2703051",
          "2703052",
          "2703053",
          "2703054"
        ],
        "spl_id": [
          "3553ca93-cbe0-4286-b806-a423598eb42a"
        ],
        "spl_set_id": [
          "472cbe04-263e-433d-9a0f-58c1b50b715a"
        ],
        "package_ndc": [
          "0002-7575-01",
          "0002-8011-01",
          "0002-8011-27",
          "0002-8011-61",
          "0002-8870-01",
          "0002-8870-27",
          "0002-7717-11",
          "0002-7717-61",
          "0002-3116-01",
          "0002-7722-11",
          "0002-1442-01",
          "0002-3116-11",
          "0002-3116-61",
          "0002-1442-11"
        ],
        "nui": [
          "N0000192799",
          "N0000192798"
        ],
        "pharm_class_epc": [
          "Interleukin-23 Antagonist [EPC]"
        ],
        "pharm_class_moa": [
          "Interleukin-23 Antagonists [MoA]"
        ],
        "unii": [
          "Z7HVY03PHP"
        ]
      },
      "update_date": "12/22/2025",
      "therapeutic_category": [
        "Gastroenterology",
        "Other"
      ],
      "dosage_form": "Injection",
      "presentation": "Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27)",
      "company_name": "Eli Lilly and Co.",
      "status": "To Be Discontinued"
    }
  ]
}